Abdulaziz AlJassim 🇵🇸
@drz_84
MRCP(UK) •KBIM •Former Fellow @OttawaHospital •Thoracic and Sarcoma Medical Oncologist • Madridista 15/36 اختصاصي أول بالأمراض الباطنية وطب الأورام وأورام الرئة
ID: 345043279
30-07-2011 00:06:31
22,22K Tweet
4,4K Takipçi
980 Takip Edilen
Our Glenwood Goss OttawaMedOnc LIVE at #ESMO24 discussing CCTG BR.31 phase 3 trial of adjuvant Durvalumab in completely resected NSCLC (1B-3A) Final Primary endpoint DFS (PD-L1>25%) 69 vs 60 HR 0.93. Neoadjuvant ChemoIO/PeriOP ChemoIO is the way to go. #lcsm
.Jordi Remon presents PECATI Lenva+pembro post platinum B3/thymic carcinoma P2. Primary: PFS at 5mo. 53% PDL1 neg. mPFS 15mo. ORR 23%. 1yr OS 85%. PFS unrelated to PFS. Lenva dose intensity longer PFS. 18.6-23.3% discont. Concludes this is a new SoC Agree. #ESMO24
GALAXIES-201 Anti-TIGIT David R. Spigel, MD, FASCO (PD-L1 high) RELATIVITY-104 Nicolas Girard Anti-LAG3 (in NSQ PD-L1 +ve) Great review by Marina Garassino New players on the field moving into phase 3.
Update Gʀᴇɢᴏʀʏ Rɪᴇʟʏ on PHAROS trial (Encorafenib + Binimetinib) for BRAFv600E mutated NSCLC ✅ Important data for treatment naive patients: ORR 75%, mPFS 30.2mo DoR 40 months mOS NE #lcsm #ESMO24
Dr. d.planchard at #ESMO24 presents phase II ENCO-BRAF study of first-line encorafenib + binimitinib in #BRAF V600E NSCLC. RR 66%, mPFS 10.9m, mOS not reached, safety shows only 3% pyrexia (no grade 3). #ESMOAmbassadors
I enjoyed the excellent review about management approach to Desmoid-type Fibromatosis and recent updates about Desmoid Global Consensus by Bernd Kasper and Alessandro Gronchi ESMO - Eur. Oncology #ESMO24 Important take home message: Active surveillance if 🚫 symptoms.